EMA Application withdrawn: Nenad (lisuride) — Axxonis Pharma AG

View source ↗

Summary

The EMA application for Nenad (lisuride) by Axxonis Pharma AG has been withdrawn for Restless Legs Syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Restless Legs Syndrome

Drugs mentioned

• Nenad (lisuride)

Snippet

Status: Application withdrawn. Therapeutic area: Restless Legs Syndrome. MAH: Axxonis Pharma AG. Decision date: 31/12/2009